Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (241-250 of 477) with videos related to

Pageof 48
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 4, 2007
Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosisDinesh Khanna, Daniel E Furst, Weng Kee Wong, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
Nutrients|January 10, 2017
Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized TrialsNinna K Senftleber, Sabrina M Nielsen, Jens R Andersen, et al.
Annals of the Rheumatic Diseases|November 5, 2014
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment periodPaul Emery, Gerd R Burmester, Vivian P Bykerk, et al.
Annals of the Rheumatic Diseases|August 31, 2021
Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral bloodYukai Wang, Xuezhen Xie, Chengpeng Zhang, et al.
The Lancet. Rheumatology|January 22, 2024
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolutionGemma Lepri, Michael Hughes, Yannick Allanore, et al.
The Journal of Rheumatology|April 17, 2017
Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudyShadi Gholizadeh, Sarah D Mills, Rina S Fox, et al.
Seminars in Arthritis and Rheumatism|December 12, 2013
Proceedings of the 5th annual perspectives in rheumatic diseasesDaniel E Furst, Brian Mandell, Leonard H Calabrese, et al.
Arthritis and Rheumatism|January 16, 2003
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialMichael E Weinblatt, Edward C Keystone, Daniel E Furst, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life StudyRina S Fox, Sarah D Mills, Shadi Gholizadeh, et al.
Pageof 48

Showing results (241-250 of 477) with videos related to

Sort By:
Pageof 48
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 4, 2007
Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosisDinesh Khanna, Daniel E Furst, Weng Kee Wong, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
Nutrients|January 10, 2017
Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized TrialsNinna K Senftleber, Sabrina M Nielsen, Jens R Andersen, et al.
Annals of the Rheumatic Diseases|November 5, 2014
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment periodPaul Emery, Gerd R Burmester, Vivian P Bykerk, et al.
Annals of the Rheumatic Diseases|August 31, 2021
Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral bloodYukai Wang, Xuezhen Xie, Chengpeng Zhang, et al.
The Lancet. Rheumatology|January 22, 2024
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolutionGemma Lepri, Michael Hughes, Yannick Allanore, et al.
The Journal of Rheumatology|April 17, 2017
Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudyShadi Gholizadeh, Sarah D Mills, Rina S Fox, et al.
Seminars in Arthritis and Rheumatism|December 12, 2013
Proceedings of the 5th annual perspectives in rheumatic diseasesDaniel E Furst, Brian Mandell, Leonard H Calabrese, et al.
Arthritis and Rheumatism|January 16, 2003
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialMichael E Weinblatt, Edward C Keystone, Daniel E Furst, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life StudyRina S Fox, Sarah D Mills, Shadi Gholizadeh, et al.
Pageof 48